Cover Image
市場調查報告書

中國的醫藥品、醫療產業(季度更新報告)

China Pharmaceuticals & Healthcare Report Q1 2018

出版商 BMI Research 商品編碼 209173
出版日期 內容資訊 英文 122 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的醫藥品、醫療產業(季度更新報告) China Pharmaceuticals & Healthcare Report Q1 2018
出版日期: 2017年11月07日 內容資訊: 英文 122 Pages
簡介

儘管經濟的減速,中國許多外資製藥企業,持續以2位數成長率伸展收益。由於人口的高齡化,個人資產的增加,政府對醫療的輔助策略等要素,預計國外投資家,今後也持續投資中國的醫藥品、醫療產業。

本報告提供中國的製藥、醫療產業結構和最新趨勢相關分析、今後10年的產業規模的動向估計、產業課題(風險)和未來商機(利潤)相關評估、政府的政策、規定、宏觀經濟環境、主要企業簡介等資訊彙整,為您概述為以下內容。

BMI的見解

SWOT分析

  • 政治
  • 經濟
  • 業務營運風險

產業預測

  • 醫藥品市場預測
  • 醫療市場預測
  • 處方藥市場預測
  • 專利藥市場預測
  • 學名藥市場預測
  • 一般用(OTC)醫藥品市場預測
  • 醫藥品的對外貿易預測
  • BMI的預測方案相關主要風險

宏觀經濟預測

  • 經濟活動

產業的風險/利潤、等級

  • 亞太地區:風險/利潤、等級
  • 中國:風險/利潤、等級
    • 利潤
    • 風險

市場概況

產業的趨勢與發展

  • 流行病學
  • 醫療部門
  • 研究開發(R&D)
  • 臨床實驗
  • 生物科技部門

法規的發展

  • 法規的體制
  • 知識產權相關課題
  • 價格決策的體制
  • 醫療費償付的體制

競爭環境

  • 研究開發意向型產業
  • 學名藥廠商
  • 醫藥品的批發業
  • 近幾年趨勢
  • 中藥

企業簡介

  • AstraZeneca
  • Bayer
  • China Shijiazhuang Pharmaceutical Group
  • Eli Lilly
  • GlaxoSmithKline
  • North China Pharmaceutical Corporation
  • Novartis
  • Merck & Co
  • Merck KGaA
  • Pfizer
  • Roche
  • Sanofi
  • Shanghai Pharmaceutical
  • Sinopharm

人口結構的預測

詞彙表

分析方法

  • 醫藥品支出額的預測模式
  • 醫療費的預測模式
  • 分析方法的相關註記
  • 風險/利潤、等級技術
  • 指標概要
  • 指標的加權

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: SSCN03_20180101

BMI View: China's evolving demographic and epidemiological profiles will act as key drivers of growth within the country's pharmaceuticals and healthcare markets over the coming years. While rising chronic diseases and developments in the healthcare system will support market expansion, tough pricing regime and a large counterfeit industry pose downside risks for multinational drugmakers. Nevertheless, the size of the market and the overall trend towards regulatory improvement will continue to prove major draws.

Table of Contents

BMI Industry View

  • Table: Headline Pharmaceuticals & Healthcare Forecasts (China 2015-2021)

SWOT

Industry Forecast

  • Pharmaceutical Market Forecast
    • Table: Pharmaceutical Sales, Historical Data And Forecasts (China 2013-2021)
  • Healthcare Market Forecast
    • Table: Healthcare Expenditure Trends, Historical Data And Forecasts (China 2013-2021)
    • Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (China 2013-2021)
    • Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (China 2013-2021)
  • Prescription Drug Market Forecast
    • Table: Prescription Drug Market Indicators, Historical Data And Forecasts (China 2013-2021)
  • Patented Drug Market Forecast
    • Table: Patented Drug Market Indicators, Historical Data And Forecasts (China 2013-2021)
  • Generic Drug Market Forecast
    • Table: Generic Drug Market Indicators, Historical Data And Forecasts (China 2013-2021)
  • OTC Market Forecast
    • Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (China 2013-2021)
  • Pharmaceutical Trade Forecast
    • Table: Pharmaceutical Trade Data And Forecasts (China 2015-2021)
    • Table: Pharmaceutical Trade Data And Forecasts local currency (China 2015-2021)

Industry Risk/Reward Index

  • Asia Pacific Pharmaceuticals: Diverse Opportunities And Inherent Risks
  • China Risk/Reward Index

Regulatory Review

  • Intellectual Property Issues
    • Table: PHRMA's Special 301 submission, China, 2014-17
  • Pricing Regime
  • China - 13th Five-Year Plan To Reinforce Existing Trends

Market Overview

  • Healthcare Sector
    • Table: Healthcare Resources (China 2011-2016)
    • Table: Healthcare Personnel (China 2011-2016)
    • Table: Healthcare Activity (China 2011-2016)
  • Research & Development
  • Clinical Trials
  • Epidemiology
    • Table: Estimated Number Of New Cases Of Cancer In China

Competitive Landscape

  • Research-Based Industry
    • Table: Multinational Market Activity
  • Generic Drugmakers
  • Pharmaceutical Distribution

Company Profile

  • AstraZeneca
  • Bayer
  • China Shijiazhuang Pharmaceutical Group
  • Eli Lilly
  • GlaxoSmithKline
  • Merck & Co
  • Merck KGaA
  • North China Pharmaceutical Corporation
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Shanghai Pharmaceutical
  • Sinopharm

Appendix

  • 13th Five-Year Plan: Key Points
  • Summary Of Contents
  • Chapter 1: Overview
    • Table: Targets
  • Chapter 2: Innovation To Drive Development
  • Chapter 3: Economic Institutions
  • Chapter 4: Modernisation Of The Agricultural Sector
  • Chapter 5: Industries
  • Chapter 6: Expand The Network Economy
  • Chapter 7: Build A Modern Infrastructure Network
  • Chapter 8: New-Type Urbanisation
  • Chapter 9: Coordination Of Regional Development
  • Chapter 10: Environmental Protection
  • Chapter 11: Continue Opening Up
  • Others:

Demographic Forecast

  • Table: Population Headline Indicators (China 1990-2025)
  • Table: Key Population Ratios (China 1990-2025)
  • Table: Urban/Rural Population & Life Expectancy (China 1990-2025)
  • Table: Population By Age Group (China 1990-2025)
  • Table: Population By Age Group % (China 1990-2025)

Glossary

Methodology

  • Pharmaceutical Expenditure Forecast Model
  • Healthcare Expenditure Forecast Model
  • Notes On Methodology
  • Risk/Reward Index Methodology
    • Table: Indicators - Rationale And Sources
Back to Top